Unresectable Metastatic Colorectal Cancer Clinical Trials

13 clinical trials for Unresectable Metastatic Colorectal Cancer across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment — RECRUITING · PHASE3
• First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer — RECRUITING · PHASE1
• Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer — RECRUITING · PHASE1
• alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells — RECRUITING · PHASE1
• EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer — NOT_YET_RECRUITING · PHASE1
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab — ACTIVE_NOT_RECRUITING · PHASE2
• SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. — NOT_YET_RECRUITING · PHASE2
• Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer — OTHER · PHASE2
• A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy — OTHER · PHASE2
• A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx — OTHER · PHASE2
• Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer — OTHER · NA
• mXELOXIRI Combined With Molecular Targeted Drug in mCRC — OTHER · PHASE2
• OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer — COMPLETED · PHASE2

Refine this search